Navigation Links
Transdel Pharmaceuticals, Inc. Retains FLP Pharma to Lead Business Development Activities
Date:2/2/2009

LA JOLLA, Calif., Feb. 2 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) (http://www.transdelpharma.com), a specialty pharmaceutical company focused on developing and commercializing non-invasive, topically administered medications, has retained FLP Pharma, a Georgia-based pharmaceutical consultancy, to lead its business development activities, especially the out-licensing of its lead product Ketotransdel(R). FLP Pharma has an experienced track record in negotiating and closing global and regional joint development, licensing, distribution, sales and marketing partnerships and supply agreements with multiple pharmaceutical companies.

"Our Phase 3 clinical trial of Ketotransdel(R) continues to advance," stated Dr. Juliet Singh, President and CEO of Transdel Pharmaceuticals. "We also continue to explore co-development opportunities in other therapeutic areas utilizing our Transdel(TM) platform technology. With the addition of FLP Pharma and its successful track record, we expect to significantly advance our partnering efforts especially for our lead pain product Ketotransdel(R) and achieve a significant milestone in our growth as a specialty pharmaceutical company."

"Transdel has implemented a focused approach in negotiating with pharmaceutical companies with a strategic interest in pain management and the requisite infrastructure to successfully commercialize Ketotransdel(R)," stated Terry Nida, Principal of FLP Pharma. "We are open to partnering with pharmaceutical companies with either a global or regional capacity to help us achieve our corporate goals."

The Company is also investigating other novel and generic drugs and promising therapeutic areas in combination with using their patented transdermal delivery system. Furthermore, the Company recently announced that they are expanding their product development programs to include cosmetic/cosmeceutical products and have initiated discussions with potential sales and marketing partners for specific products.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP - News) is a specialty pharmaceutical company developing non-invasive, topically-delivered medications. The Company's innovative patented proprietary Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of drugs through the tough skin barrier to reach the target underlying tissues. In the case of Ketotransdel(R), the Transdel(TM) cream allows the active ingredient ketoprofen, a non-steroidal anti-inflammatory drug, to reach the target soft tissue and exert its well-known anti-inflammatory and analgesic effects. The Company is also investigating other drug candidates and treatments for transdermal delivery using the Transdel(TM) platform technology for products in pain management and other therapeutic areas and for cosmetic/cosmeceutical products. For more information, please visit http://www.transdelpharma.com.

About FLP Pharma LLC

A Pharmaceutical Consulting Service with more than thirty years of international management experience in specialty pharmaceutical, biotech and fully integrated companies; with extensive experience in negotiating licensing agreements for global and regional territories. For more information, please visit www.FLPPharma.com.

Safe Harbor Statement

Statements made in this release that are not historical in nature constitute forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, and technological changes. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-KSB filed with the SEC on March 26, 2008. Such documents may be read free of charge on the SEC's web site at www.sec.gov. All forward-looking statements included in this release are made as of the date of this press release, and the Company assumes no obligation to update any such forward-looking statements.


'/>"/>
SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Transdel Expands Program to Include Cosmetic/Cosmeceutical Products
2. Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the Presidents Council on Physical Fitness and Sports, to Board of Directors
3. Transdel Pharmaceuticals to Present at Cowen and Companys 28th Annual Health Care Conference
4. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
5. Genesis Pharmaceuticals Enters Into Agreement to Purchase Hongrui Pharmaceuticals, and Acquire 22 New Traditional Chinese Medicines
6. Renhuang Pharmaceuticals, Inc. Engages New Independent Auditor
7. Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements
8. Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
9. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
10. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... ... Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s ... bundles, which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use ...
(Date:4/24/2017)... ... , ... Ridgecrest Herbals makes it a point to lead the Utah supplement ... support renewable energy. They believe this is a crucial part of their mission as ... issues, and maintain that destroying the environment in the pursuit of profit is unsustainable ...
(Date:4/24/2017)... ... 2017 , ... The bar for just about everything—apparel, eyewear, cars and even ... of pop and film stardom.(1) Not to be left out is that most desired ... run the gamut from being encrusted with jewels and precious metals to, at the ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Sean Fay ... Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold ... any other marketer in the last 25 years. , Now, due to changes in ...
(Date:4/24/2017)... ... April 24, 2017 , ... ALP Nutrition®, a ... announced its popular products are now available for purchase on StackedNutrition.com, a popular ... use of premium natural ingredients in making all of its products. These ingredients ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), ... Forecasts, 2014 - 2025" report to their offering. ... The Latin American pharmaceutical ... billion by 2025 Low drug registration cost in ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
Breaking Medicine Technology: